Zoono Group (ASX:ZNO) - Managing Director & CEO, Paul Hyslop (Second from left)
Managing Director & CEO, Paul Hyslop (Second from left)
Source: Zoono Group
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Zoono Group’s (ZNO) Z-71 Microbe Shield surface sanitiser has been successfully tested against COVID-19
  • Laboratory tests show the product is more than 99.99 per cent effective against the virus
  • Z-71 is the same technology used in the company’s hand sanitiser
  • Zoono’s products are known to protect humans against a variety of viruses for up to 30 days on surfaces and 24 hours on hands
  • Zoono is up 9.26 per cent on the market this morning, trading at $1.77 per share

Zoono Group’s (ZNO) Z-71 Microbe Shield surface sanitiser has been successfully tested against the recent coronavirus (COVIOD-19).

Laboratory tests show the product is more than 99.99 per cent effective against the virus.

COVID-19 has become a global concern and has been shown to survive on surfaces for up to nine days. Zoono products have been successfully tested against a variety of pathogens for up to 30 days on surfaces and 24 hours on hands.

Z-71 was previously tested against bovine coronavirus, however, this latest strain required new testing.

The company conducted two separate tests to EN Standard 14476:2013+A2:2019 for chemical disinfectants and antiseptics.

EN14476 is the European Standard that applies to products within the medical area, this includes hygienic hand rubs, hygienic hand wash, instrument disinfection by immersion, surface disinfection by wiping, spraying, flooding and others.

Z-71 Microbe Shield is the same technology used in the company’s hand sanitisers.

“Zoono is very pleased with the results which further demonstrates the ability of the Zoono technology to be part of the solution to prevent and protect against the spread of the COVID19 Virus,” the company told the market.

Zoono is up 9.26 per cent on the market this morning, trading at $1.77 per share at 11:31 am AEDT.

ZNO by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…